Alicia C. Olivo, Executive Vice President, General Counsel and Business Development officer of NeoGenomics Inc, filed a Form 4 on September 3, 2026, reporting a share disposition on September 1, 2026, in connection with a restricted stock vesting event.

Key Highlights

  • Shares surrendered: Olivo disposed of 2,692 shares of common stock at $0 per share on September 1, 2026, to satisfy tax obligations tied to a restricted stock vesting.
  • Post-transaction ownership: Following the transaction, Olivo directly holds 90,875 shares of common stock.
  • Transaction code: The disposition was coded "F," indicating shares withheld for tax withholding purposes, not an open-market sale.
  • Derivative holdings: Olivo holds stock options across multiple grant dates with exercise prices ranging from $9.45 to $48.99, plus additional premium-price options at $13.05 and $10.81.
  • Largest option grant: A March 1, 2026 premium-price grant of 147,804 stock options at $10.81, vesting ratably over three years, is among Olivo's most recent equity awards.
  • Recent RSU grant: On March 1, 2026, Olivo also received 89,013 restricted stock units, vesting ratably over the first three anniversary dates of the grant date.

NeoGenomics EVP Discloses Tax-Related Share Forfeiture and Full Derivative Holdings

According to the filing, Alicia C. Olivo, serving as EVP, GC and Business Development at NeoGenomics Inc (NASDAQ:NEO), reported a single non-derivative transaction on September 1, 2026. The 2,692 shares disposed of were "surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the September 1, 2026 vesting of restricted stock," as stated in the filing's explanation of responses. The transaction price was recorded as $0, consistent with a tax withholding surrender rather than a market sale. After this disposition, Olivo directly owns 90,875 shares of common stock.

The filing also provides a comprehensive view of Olivo's derivative securities. She holds stock options from grants dating back to September 2019, with exercise prices ranging from $9.45 to $48.99 per share, as well as two premium-price stock options: 107,450 options at $13.05 granted February 21, 2025, and 147,804 options at $10.81 granted March 1, 2026. Both premium-price options were calculated by multiplying the applicable closing price by 110%, according to the filing. All option grants vest ratably over either three or four anniversary dates of their respective grant dates.

In addition to stock options, the filing discloses restricted stock units and performance stock units from multiple grant cycles. Notable among these is a May 11, 2023 performance stock unit grant of 19,508 units at target, with a maximum of 29,262 shares that may vest based on share growth goals. A February 23, 2024 performance stock unit grant of 25,330 units at target carries a maximum of 37,996 shares, with vesting split equally between share growth and cumulative revenue growth criteria, according to the filing.

What Was Disclosed

The filing reports a tax-withholding surrender of 2,692 common shares by NeoGenomics EVP Alicia C. Olivo on September 1, 2026, leaving her with 90,875 directly held shares, alongside extensive derivative security holdings across numerous grant dates.